265 related articles for article (PubMed ID: 28746363)
1. MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.
Hora M; Sarkar R; Morris V; Xue K; Prade E; Harding E; Buchner J; Reif B
PLoS One; 2017; 12(7):e0181799. PubMed ID: 28746363
[TBL] [Abstract][Full Text] [Related]
2. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
3. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
[TBL] [Abstract][Full Text] [Related]
4. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
5. A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding.
Khurana R; Souillac PO; Coats AC; Minert L; Ionescu-Zanetti C; Carter SA; Solomon A; Fink AL
Amyloid; 2003 Jun; 10(2):97-109. PubMed ID: 12964417
[TBL] [Abstract][Full Text] [Related]
6. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
[TBL] [Abstract][Full Text] [Related]
8. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
9. Solid-state NMR chemical shift assignments for AL-09 V
Piehl DW; Blancas-Mejía LM; Ramirez-Alvarado M; Rienstra CM
Biomol NMR Assign; 2017 Apr; 11(1):45-50. PubMed ID: 27771830
[TBL] [Abstract][Full Text] [Related]
10. The folding pathway of the antibody V(L) domain.
Simpson ER; Herold EM; Buchner J
J Mol Biol; 2009 Oct; 392(5):1326-38. PubMed ID: 19647749
[TBL] [Abstract][Full Text] [Related]
11. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation.
Qin Z; Hu D; Zhu M; Fink AL
Biochemistry; 2007 Mar; 46(11):3521-31. PubMed ID: 17315948
[TBL] [Abstract][Full Text] [Related]
13. The Antibody Light-Chain Linker Is Important for Domain Stability and Amyloid Formation.
Nokwe CN; Hora M; Zacharias M; Yagi H; John C; Reif B; Goto Y; Buchner J
J Mol Biol; 2015 Nov; 427(22):3572-3586. PubMed ID: 26408269
[TBL] [Abstract][Full Text] [Related]
14. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH.
Souillac PO; Uversky VN; Millett IS; Khurana R; Doniach S; Fink AL
J Biol Chem; 2002 Apr; 277(15):12657-65. PubMed ID: 11815605
[TBL] [Abstract][Full Text] [Related]
15. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
16. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
Kim YS; Cape SP; Chi E; Raffen R; Wilkins-Stevens P; Stevens FJ; Manning MC; Randolph TW; Solomon A; Carpenter JF
J Biol Chem; 2001 Jan; 276(2):1626-33. PubMed ID: 11050093
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.
DiCostanzo AC; Thompson JR; Peterson FC; Volkman BF; Ramirez-Alvarado M
J Biol Chem; 2012 Aug; 287(33):27997-8006. PubMed ID: 22740699
[TBL] [Abstract][Full Text] [Related]
18. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
19. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation.
Kim YS; Randolph TW; Manning MC; Stevens FJ; Carpenter JF
J Biol Chem; 2003 Mar; 278(12):10842-50. PubMed ID: 12529361
[TBL] [Abstract][Full Text] [Related]
20. The amyloid fibrils of the constant domain of immunoglobulin light chain.
Yamamoto K; Yagi H; Lee YH; Kardos J; Hagihara Y; Naiki H; Goto Y
FEBS Lett; 2010 Aug; 584(15):3348-53. PubMed ID: 20580354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
